拉索昔芬对比氟维司群治疗伴ESR1突变的ER+/HER2-转移性乳腺癌:随机II期ELAINE 1试验结果
ELAINE 1是一项开放标签、随机、II期、多中心研究,纳入103例经芳香化酶抑制剂联合CDK4/6抑制剂治疗后进展的ESR1突变、ER+/HER2-转移性乳腺癌女性,随机接受口服拉索昔芬5 mg每日一次或肌注氟维司群500 mg。主要终点无进展生存期(PFS)在两组间无显著差异:拉索昔芬组24.2周 vs 氟维司群组16.2周(P=0.138),风险比0.699(95%CI 0.434-1.125)。拉索昔芬耐受性良好,可降低ESR1突变等位基因分数,且降幅大于氟维司群,作者认为值得进一步研究。
要点
- 拉索昔芬组中位PFS 24.2周 vs 氟维司群组16.2周,差异无统计学显著(P=0.138;HR 0.699,95%CI 0.434-1.125)。
- 临床获益率拉索昔芬组36.5% vs 氟维司群组21.6%(P=0.117),客观缓解率13.2% vs 2.9%(P=0.124),均未达统计学显著。
- 拉索昔芬组最常见治疗中出现的不良事件为恶心、疲乏、关节痛和潮热;氟维司群组发生1例死亡。
核心结论
- 拉索昔芬在经芳香化酶抑制剂联合CDK4/6抑制剂治疗后进展的ESR1突变、内分泌耐药转移性乳腺癌患者中,相较氟维司群显示出令人鼓舞的抗肿瘤活性且耐受性良好。
- 拉索昔芬可降低ESR1突变等位基因分数,且降幅大于氟维司群,与靶点结合一致;作者认为拉索昔芬可能是ESR1突变转移性乳腺癌有前景的靶向治疗,值得进一步研究。
研究设计与样本
- 开放标签、随机、II期、多中心ELAINE 1研究(NCT03781063)。
- 纳入ESR1突变、ER+/HER2-转移性乳腺癌女性,经芳香化酶抑制剂联合CDK4/6抑制剂治疗后进展。
- 随机接受口服拉索昔芬5 mg每日一次(n=52)或肌注氟维司群500 mg(第1、15、29天,之后每4周一次;n=51),直至疾病进展或毒性。
- 主要终点为无进展生存期(PFS),次要终点为安全性/耐受性。
主要发现
- 拉索昔芬组中位PFS 24.2周(约5.6个月) vs 氟维司群组16.2周(约3.7个月),差异无统计学显著(P=0.138);风险比0.699(95%CI 0.434-1.125)。
- 临床获益率拉索昔芬组36.5% vs 氟维司群组21.6%(P=0.117)。
- 客观缓解率拉索昔芬组13.2%(含1例完全缓解) vs 氟维司群组2.9%(P=0.124)。
- 6个月PFS率拉索昔芬组53.4% vs 氟维司群组37.9%;12个月PFS率拉索昔芬组30.7% vs 氟维司群组14.1%。
- 循环肿瘤DNA ESR1突变等位基因分数从基线至第8周下降者比例:拉索昔芬组82.9%(可评估者) vs 氟维司群组61.5%。
关键数值与推荐
- 拉索昔芬组最常见治疗中出现的不良事件为恶心、疲乏、关节痛和潮热。
- 氟维司群组发生1例死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性;作者在结论中提出拉索昔芬值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acquired estrogen receptor alpha (ER/ESR1) mutations commonly cause endocrine resistance in ER+ metastatic breast cancer (mBC). Lasofoxifene, a novel selective ER modulator, stabilizes an antagonist conformation of wild-type and ESR1-mutated ER-ligand binding domains, and has antitumor activity in ESR1-mutated xenografts. PATIENTS AND METHODS: In this open-label, randomized, phase II, multicenter, ELAINE 1 study (NCT03781063), we randomized women with ESR1-mutated, ER+/human epidermal growth factor receptor 2 negative (HER2-) mBC that had progressed on an aromatase inhibitor (AI) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) to oral lasofoxifene 5 mg daily or IM fulvestrant 500 mg (days 1, 15, and 29, and then every 4 weeks) until disease progression/toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were safety/tolerability. RESULTS: A total of 103 patients received lasofoxifene (n = 52) or fulvestrant (n = 51). The most current efficacy analysis showed that lasofoxifene did not significantly prolong median PFS compared with fulvestrant: 24.2 weeks (∼5.6 months) versus 16.2 weeks (∼3.7 months; P = 0.138); hazard ratio 0.699 (95% confidence interval 0.434-1.125). However, PFS and other clinical endpoints numerically favored lasofoxifene: clinical benefit rate (36.5% versus 21.6%; P = 0.117), objective response rate [13.2% (including a complete response in one lasofoxifene-treated patient) versus 2.9%; P = 0.124], and 6-month (53.4% versus 37.9%) and 12-month (30.7% versus 14.1%) PFS rates. Most common treatment-emergent adverse events with lasofoxifene were nausea, fatigue, arthralgia, and hot flushes. One death occurred in the fulvestrant arm. Circulating tumor DNA ESR1 mutant allele fraction (MAF) decreased from baseline to week 8 in 82.9% of evaluable lasofoxifene-treated versus 61.5% of fulvestrant-treated patients. CONCLUSIONS: Lasofoxifene demonstrated encouraging antitumor activity versus fulvestrant and was well tolerated in patients with ESR1-mutated, endocrine-resistant mBC following progression on AI plus CDK4/6i. Consistent with target engagement, lasofoxifene reduced ESR1 MAF, and to a greater extent than fulvestrant. Lasofoxifene may be a promising targeted treatment for patients with ESR1-mutated mBC and warrants further investigation.
引用
- Goetz MP, Bagegni NA, Batist G, et al. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023. PMID: 38072514. doi:10.1016/j.annonc.2023.09.3104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。